Recruiting
Phase 1

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Sponsor:

IRIS Research and Development, LLC

Code:

NCT06581562

Conditions

Rheumatoid Arthritis

Pemphigus Vulgaris

Granulomatosis With Polyangiitis

Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AB-101

Rituximab

Cyclophosphamide

Fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information